PUBLISHED DATE : Oct 2023 | Pages : 305
Fill out your details & get your free sample
The Cardiac Biomarkers Market Size, Share, & Trends Analysis Report by
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2023–2028.
305 Pages
140 Tables
117 Charts
5 Regions
18 Countries
22 Companies
4 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2028) | USD 26.43 Billion |
| Market Size (2022) | USD 13.29 Billion |
| CAGR (2022-2028) | 12.14% |
| Base Year | 2022 |
| Forecast Year | 2023-2028 |
| Market Segments | Biomarkers Type, Application, End-user, and Geography |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| KEY VENDORS | Abbott, Bio-Rad Laboratories, Danaher, F. Hoffmann-La Roche, PerkinElmer, and Siemens Healthineers |
The global cardiac biomarkers market was valued at USD 13.29 billion in 2022 and is expected to reach USD 26.43 billion by 2028, growing at a CAGR of 12.14% during the forecast period. The global market encompasses the products, technologies, and services related to detecting, measuring, and utilizing cardiac biomarkers in clinical practice. The cardiac biomarkers market has experienced significant growth due to the increasing prevalence of cardiovascular diseases, a growing aging population, and advancements in diagnostic technologies.
Cardiac biomarkers are specific molecules or proteins released into the bloodstream in response to various physiological changes within the heart. These biomarkers provide crucial information about the heart's health, function, and potential cardiac damage or stress. They diagnose and monitor cardiovascular conditions, including heart attacks, heart failure, and other heart-related diseases. The levels of these biomarkers can help healthcare professionals assess the severity of cardiac events, predict outcomes, guide treatment decisions, and monitor patients' responses to interventions. As medical technology continues to evolve, the cardiac biomarkers market is expected to witness ongoing innovation, leading to the development of more accurate, rapid, and user-friendly diagnostic tools. Integrating digital health solutions and artificial intelligence into biomarker testing will shape the cardiac biomarkers market's future.
Cardiac biomarkers play a pivotal role in diagnosing and managing cardiovascular diseases. The increasing prevalence of heart-related conditions and technological advancements drive the global market for these biomarkers. With the potential to enhance patient outcomes and improve healthcare strategies, cardiac biomarkers are at the forefront of modern cardiovascular diagnostics. Furthermore, the cardiac biomarkers market is a dynamic landscape characterized by intense competition and continuous innovation. Established healthcare giants and emerging biotechnology firms, various vendors contribute to advancing cardiovascular diagnostics through their products, research, and strategic initiatives. Leading vendors are committed to raising awareness among healthcare professionals and the general public about the significance of cardiac biomarkers. Education initiatives highlight the role of biomarkers in early detection, prevention, and management of cardiovascular diseases.
Integration of Multiple Cardiac Biomarkers
Healthcare professionals increasingly recognize the value of combining information from various biomarkers to understand a patient's cardiac health comprehensively. This approach allows for more accurate risk assessment, early detection of cardiovascular diseases, and personalized treatment strategies. By analyzing multiple biomarkers simultaneously, clinicians can provide more tailored care and improve patient outcomes in a field where precision and timely intervention are crucial.
Increasing R&D Activities of Novel Cardiac Biomarkers
The cardiac biomarkers market is witnessing a significant trend of increasing research and development (R&D) activities focused on novel cardiac biomarkers. Researchers and companies are exploring innovative molecular indicators to enhance diagnostic accuracy, risk assessment, and personalized treatment strategies for cardiovascular diseases. This trend reflects a growing commitment to advancing cardiac diagnostics, leading to the discovery of new biomarkers that can provide deeper insights into heart health, enabling early detection and improved patient outcomes.
Growing Prevalence of Cardiovascular Diseases
The escalating prevalence of CVDs is a significant driving force for the cardiac biomarkers market. With CVDs becoming a leading cause of global mortality, there's a heightened need for accurate and timely diagnosis. Cardiac biomarkers offer critical insights into heart health, enabling early detection, precise risk assessment, and effective monitoring. As the burden of CVDs continues to rise, the demand for biomarker-based diagnostic tools is growing, facilitating proactive healthcare interventions and ultimately contributing to improved patient outcomes.
Increasing Demand for Point-of-care Cardiac Diagnostics
The cardiac biomarkers market is witnessing a surge in demand due to the increasing recognition of the value of point-of-care cardiac diagnostics. Healthcare providers are embracing rapid and convenient testing methods that offer real-time cardiac insights at the patient's bedside or in emergency settings. This trend is driven by the need for timely diagnosis and treatment of cardiovascular diseases, enhancing patient outcomes. The convenience and speed of point-of-care testing are reshaping the market, allowing for quicker interventions, risk assessment, and treatment monitoring, ultimately improving heart health management on a global scale.
Advancements in Cardiac Biomarkers
Advancements in cardiac biomarkers are propelling the growth of the cardiac biomarkers market by revolutionizing cardiovascular diagnostics. High-sensitivity assays enable early detection and precise monitoring of subtle biomarker changes, enhancing diagnostic accuracy. Integration with point-of-care testing devices accelerates real-time decision-making, which is crucial in emergencies. Digital connectivity and artificial intelligence empower personalized patient management, transforming treatment strategies. These advancements enhance the overall efficiency of cardiac care, attracting investments and driving market expansion globally.
INSIGHTS BY BY BIOMARKERS TYPE
The global cardiac biomarkers market by biomarkers type can be classified as troponin, creatine kinase (CK-MB), myoglobin, and others. The troponin segment accounted for the largest industry share in 2022. Troponins are a group of cardiac biomarkers that have revolutionized diagnosing and managing CVDs. They are specific proteins found in cardiac muscle cells and are released into the bloodstream when there is damage to the heart muscle. Troponin biomarkers are pivotal in identifying cardiac conditions, assessing the severity of cardiac events, guiding treatment decisions, and predicting patient outcomes. Further, high-sensitivity troponin assays enhance this early detection capability, identifying small amounts of troponin in the blood, even without clinical symptoms.
INSIGHTS BY APPLICATION
The acute coronary syndrome (ACS) application segment accounted for the largest global cardiac biomarkers market share in 2022. Acute coronary syndrome (ACS) encompasses a spectrum of clinical conditions caused by a sudden reduction or cessation of blood flow to the heart muscle due to atherosclerotic plaque rupture or erosion. Timely and accurate diagnosis of ACS is critical for guiding appropriate management and reducing morbidity and mortality. Cardiac biomarkers play a pivotal role in the assessment of ACS, aiding in the identification, risk stratification, and treatment of patients with this life-threatening condition. Cardiac biomarkers not only aid in diagnosing ACS and risk stratification but also play a role in guiding treatment decisions. Elevated cardiac biomarkers indicate myocardial injury, emphasizing the need for immediate antiplatelet therapy, such as aspirin or P2Y12 inhibitors, to prevent further clot formation.
INSIGHTS BY END-USER
The global cardiac biomarkers market by end-user is segmented into hospitals, diagnostic laboratories, and others. In 2022, hospitals accounted for a significant share of the end-user segment. Hospitals serve as vital end-users of cardiac biomarkers, utilizing them in various aspects of patient care related to cardiovascular diseases. From the emergency department to inpatient settings, cardiac biomarkers are pivotal in diagnosing acute cardiovascular events, risk-stratifying patients, and guiding treatment decisions. These biomarkers' availability and accurate interpretation enable healthcare professionals to provide timely interventions and improve patient outcomes. By leveraging the power of cardiac biomarkers, hospitals can continue to make significant strides in improving the care and outcomes of patients with cardiovascular conditions.
North America held the most prominent global cardiac biomarkers market share in 2022. The region's leadership is attributed to factors such as the high prevalence of CVDs, a well-established healthcare infrastructure, and robust research and development activities. The U.S. and Canada are the primary contributors to the market's growth in this region, with a focus on introducing innovative biomarkers and diagnostic technologies. Moreover, increasing awareness about early disease detection and prevention drives the adoption of cardiac biomarkers in clinical practice.
Europe holds a significant share of the global cardiac biomarkers market due to the rising incidence of CVDs and an aging population. Countries such as Germany, France, the UK, Italy, and Spain are at the forefront of technological advancements and medical research in cardiovascular medicine. Additionally, government initiatives to improve healthcare facilities and reduce CVD-related morbidity and mortality further boost the adoption of cardiac biomarkers in Europe.
The field of cardiac biomarkers has experienced significant growth and innovation over the past few decades, playing a pivotal role in diagnosing, prognosis, and managing CVDs. As one of the most critical segments within the broader healthcare industry, the global cardiac biomarkers market has become a competition hub, driven by the increasing prevalence of CVDs, advancements in diagnostic technologies, and the pursuit of improved patient outcomes. Furthermore, the cardiac biomarkers market is characterized by various players, including pharmaceutical companies, diagnostic manufacturers, biotechnology firms, and research institutions. Prominent global cardiac biomarkers market players include Abbott, Bio-Rad Laboratories, Danaher, F. Hoffman-La Roche, PerkinElmer, and Siemens Healthineers. These industry giants have historically dominated the landscape due to their extensive resources, established distribution networks, and intense research and development capabilities.
The constant quest for improved diagnostic accuracy, faster results, and personalized patient care drives competition in the cardiac biomarkers market. Abbott is a prominent player in the cardiac biomarkers market, offering various diagnostic solutions that help healthcare professionals diagnose, monitor, and manage cardiovascular diseases (CVDs). Cardiovascular diseases, including heart attacks, heart failure, and arrhythmias, remain a leading cause of mortality globally. The company continues to invest in research and development to enhance its cardiac biomarkers offerings.
Frequently Asked Questions
How big is the global cardiac biomarkers market?
The global cardiac biomarkers market size was valued at USD 13.29 billion in 2022 and is expected to reach USD 26.43 billion by 2028.
What is the projected growth rate of the global cardiac biomarkers market?
The global cardiac biomarkers market is projected to grow at a CAGR of 12.14% during the forecast period.
What are the rising trends in the cardiac biomarkers market?
The rising trends in the cardiac biomarkers market are the development of highly sensitive biomarkers for risk stratification, integration of multiple cardiac biomarkers, and increasing R&D activities of novel cardiac biomarkers.
Which region holds the most significant global cardiac biomarkers market share?
North America dominated the global cardiac biomarkers market share, accounting for over 41% in 2022.
Who are the key players in the global cardiac biomarkers market?
Abbott, Bio-Rad Laboratories, Danaher, F. Hoffmann-La Roche, PerkinElmer, and Siemens Healthineers are the key players in the global cardiac biomarkers market.
The global cardiac biomarkers market size is expected to grow at a CAGR of approximately 12.14% from 2022 to 2028.
The following factors are likely to contribute to the growth of the cardiac biomarkers market during the forecast period:
Base Year: 2022
Forecast Year: 2023-2028
The report considers the present scenario of the cardiac biomarkers market and its market dynamics for 2023−2028. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.
Key Company Profiles
Other Prominent Vendors
Segmentation by Biomarkers Type
Segmentation by Application
Segmentation by End-user
Segmentation by Geography
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY BIOMARKERS TYPE
4.3.2 MARKET SEGMENTATION BY APPLICATION
4.3.3 MARKET SEGMENTATION BY END-USER
4.3.4 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 PREMIUM INSIGHTS
7.1 OVERVIEW
7.1.1 GEOGRAPHY INSIGHTS
7.1.2 BIOMARKERS TYPE INSIGHTS
7.1.3 APPLICATION INSIGHTS
7.1.4 END-USER INSIGHTS
8 INTRODUCTION
8.1 OVERVIEW
9 MARKET OPPORTUNITIES & TRENDS
9.1 DEVELOPMENT OF HIGHLY SENSITIVE BIOMARKERS FOR RISK STRATIFICATION
9.2 INTEGRATION OF MULTIPLE CARDIAC BIOMARKERS
9.3 INCREASING R&D ACTIVITIES OF NOVEL CARDIAC BIOMARKERS
10 MARKET GROWTH ENABLERS
10.1 GROWING PREVALENCE OF CARDIOVASCULAR DISEASES
10.2 INCREASING DEMAND FOR POINT-OF-CARE CARDIAC DIAGNOSTICS
10.3 ADVANCES IN CARDIAC BIOMARKERS
11 MARKET RESTRAINTS
11.1 LACK OF SPECIFICITY OF CARDIAC BIOMARKERS
11.2 AVAILABILITY OF NON-LABORATORY TESTS & GENERAL TESTS
11.3 FALSE DISCOVERIES IN CARDIAC BIOMARKERS RESEARCH
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.3 MARKET OPPORTUNITY
12.3.1 MARKET BY GEOGRAPHY
12.3.2 MARKET BY BIOMARKERS TYPE
12.3.3 MARKET BY APPLICATION
12.3.4 MARKET BY END-USER
12.4 FIVE FORCES ANALYSIS
12.4.1 THREAT OF NEW ENTRANTS
12.4.2 BARGAINING POWER OF SUPPLIERS
12.4.3 BARGAINING POWER OF BUYERS
12.4.4 THREAT OF SUBSTITUTES
12.4.5 COMPETITIVE RIVALRY
13 BIOMARKERS TYPE
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 TROPONIN
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 TROPONIN MARKET BY GEOGRAPHY
13.4 CREATINE KINASE (CK-MB)
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 CREATINE KINASE (CK-MB) MARKET BY GEOGRAPHY
13.5 MYOGLOBIN
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST
13.5.3 MYOGLOBIN MARKET BY GEOGRAPHY
13.6 OTHER
13.6.1 MARKET OVERVIEW
13.6.2 MARKET SIZE & FORECAST
13.6.3 OTHER MARKET BY GEOGRAPHY
14 APPLICATION
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.1 ACUTE CORONARY SYNDROME
14.1.1 MARKET OVERVIEW
14.1.2 MARKET SIZE & FORECAST
14.1.3 ACUTE CORONARY SYNDROME MARKET BY GEOGRAPHY
14.2 MYOCARDIAL INFRACTION
14.2.1 MARKET OVERVIEW
14.2.2 MARKET SIZE & FORECAST
14.2.3 MYOCARDIAL INFRACTION MARKET BY GEOGRAPHY
14.3 CONGESTIVE HEART FAILURE
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 CONGESTIVE HEART FAILURE MARKET BY GEOGRAPHY
14.4 OTHER
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 OTHER MARKET BY GEOGRAPHY
15 END-USER
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 HOSPITALS
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.3.3 HOSPITALS MARKET BY GEOGRAPHY
15.4 DIAGNOSTIC LABORATORIES
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.4.3 DIAGNOSTIC LABORATORIES MARKET BY GEOGRAPHY
15.5 OTHER
15.5.1 MARKET OVERVIEW
15.5.2 MARKET SIZE & FORECAST
15.5.3 OTHER MARKET BY GEOGRAPHY
16 GEOGRAPHY
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 GEOGRAPHIC OVERVIEW
17 NORTH AMERICA
17.1 MARKET OVERVIEW
17.2 MARKET SIZE & FORECAST
17.2.1 NORTH AMERICA MARKET BY BIOMARKER TYPE
17.2.2 NORTH AMERICA MARKET BY APPLICATION
17.2.3 NORTH AMERICA MARKET BY END-USER
17.3 KEY COUNTRIES
17.4 US
17.4.1 MARKET SIZE & FORECAST
17.5 CANADA
17.5.1 MARKET SIZE & FORECAST
18 EUROPE
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.2.1 EUROPE MARKET BY BIOMARKER TYPE
18.2.2 EUROPE MARKET BY APPLICATION
18.2.3 EUROPE MARKET BY END-USER
18.3 KEY COUNTRIES
18.4 GERMANY
18.4.1 MARKET SIZE & FORECAST
18.5 FRANCE
18.5.1 MARKET SIZE & FORECAST
18.6 UK
18.6.1 MARKET SIZE & FORECAST
18.7 ITALY
18.7.1 MARKET SIZE & FORECAST
18.8 SPAIN
18.8.1 MARKET SIZE & FORECAST
19 APAC
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.2.1 APAC MARKET BY BIOMARKER TYPE
19.2.2 APAC MARKET BY APPLICATION
19.2.3 APAC MARKET BY END-USER
19.3 KEY COUNTRIES
19.4 JAPAN
19.4.1 MARKET SIZE & FORECAST
19.5 CHINA
19.5.1 MARKET SIZE & FORECAST
19.6 INDIA
19.6.1 MARKET SIZE & FORECAST
19.7 SOUTH KOREA
19.7.1 MARKET SIZE & FORECAST
19.8 AUSTRALIA
19.8.1 MARKET SIZE & FORECAST
20 LATIN AMERICA
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.2.1 LATIN AMERICA MARKET BY BIOMARKER TYPE
20.2.2 LATIN AMERICA MARKET BY APPLICATION
20.2.3 LATIN AMERICA MARKET BY END-USER
20.3 KEY COUNTRIES
20.4 BRAZIL
20.4.1 MARKET SIZE & FORECAST
20.5 MEXICO
20.5.1 MARKET SIZE & FORECAST
20.6 ARGENTINA
20.6.1 MARKET SIZE & FORECAST
21 MIDDLE EAST & AFRICA
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.2.1 MIDDLE EAST & AFRICA MARKET BY BIOMARKER TYPE
21.2.2 MIDDLE EAST & AFRICA MARKET BY APPLICATION
21.2.3 MIDDLE EAST & AFRICA MARKET BY END-USER
21.3 KEY COUNTRIES
21.4 TURKEY
21.4.1 MARKET SIZE & FORECAST
21.5 SOUTH AFRICA
21.5.1 MARKET SIZE & FORECAST
21.6 SAUDI ARABIA
21.6.1 MARKET SIZE & FORECAST
22 COMPETITIVE LANDSCAPE
22.1 COMPETITION OVERVIEW
22.2 MARKET SHARE ANALYSIS
22.2.1 ABBOTT
22.2.2 BIO-RAD LABORATORIES
22.2.3 DANAHER
22.2.4 F. HOFFMANN-LA ROCHE
22.2.5 PERKINELMER
22.2.6 SIEMENS HEALTHINEERS
23 KEY COMPANY PROFILES
23.1 ABBOTT
23.1.1 BUSINESS OVERVIEW
23.1.2 PRODUCT OFFERINGS
23.1.3 KEY STRATEGIES
23.1.4 KEY STRENGTHS
23.1.5 KEY OPPORTUNITIES
23.2 BIO-RAD LABORATORIES
23.2.1 BUSINESS OVERVIEW
23.2.2 PRODUCT OFFERINGS
23.2.3 KEY STRATEGIES
23.2.4 KEY STRENGTHS
23.2.5 KEY OPPORTUNITIES
23.3 DANAHER
23.3.1 BUSINESS OVERVIEW
23.3.2 PRODUCT OFFERINGS
23.3.3 KEY STRATEGIES
23.3.4 KEY STRENGTHS
23.3.5 KEY OPPORTUNITIES
23.4 F. HOFFMANN-LA ROCHE
23.4.1 BUSINESS OVERVIEW
23.4.2 PRODUCT OFFERINGS
23.4.3 KEY STRATEGIES
23.4.4 KEY STRENGTHS
23.4.5 KEY OPPORTUNITIES
23.5 PERKINELMER
23.5.1 BUSINESS OVERVIEW
23.5.2 PRODUCT OFFERINGS
23.5.3 KEY STRATEGIES
23.5.4 KEY STRENGTHS
23.5.5 KEY OPPORTUNITIES
23.6 SIEMENS HEALTHINEERS
23.6.1 BUSINESS OVERVIEW
23.6.2 PRODUCT OFFERINGS
23.6.3 KEY STRATEGIES
23.6.4 KEY STRENGTHS
23.6.5 KEY OPPORTUNITIES
24 OTHER PROMINENT VENDORS
24.1 ABCAM
24.1.1 BUSINESS OVERVIEW
24.1.2 PRODUCT OFFERINGS
24.2 BIOMÉRIEUX
24.2.1 BUSINESS OVERVIEW
24.2.2 PRODUCT OFFERINGS
24.3 BIOSUPPLY
24.3.1 BUSINESS OVERVIEW
24.3.2 PRODUCT OFFERINGS
24.4 BTNX
24.4.1 BUSINESS OVERVIEW
24.4.2 PRODUCT OFFERINGS
24.5 CARDIOGENICS
24.5.1 BUSINESS OVERVIEW
24.5.2 PRODUCT OFFERINGS
24.6 CREATIVE DIAGNOSTICS
24.6.1 BUSINESS OVERVIEW
24.6.2 PRODUCT OFFERINGS
24.7 DIASORIN
24.7.1 BUSINESS OVERVIEW
24.7.2 PRODUCT OFFERINGS
24.8 LIFE DIAGNOSTICS
24.8.1 BUSINESS OVERVIEW
24.8.2 PRODUCT OFFERINGS
24.9 LUMIRADX
24.9.1 BUSINESS OVERVIEW
24.9.2 PRODUCT OFFERINGS
24.10 MEDIX BIOCHEMICA
24.10.1 BUSINESS OVERVIEW
24.10.2 PRODUCT OFFERINGS
24.11 MESO SCALE DIAGNOSTICS
24.11.1 BUSINESS OVERVIEW
24.11.2 PRODUCT OFFERINGS
24.12 MP BIOMAEDICALS
24.12.1 BUSINESS OVERVIEW
24.12.2 PRODUCT OFFERINGS
24.13 QUIDEL
24.13.1 BUSINESS OVERVIEW
24.13.2 PRODUCT OFFERINGS
24.14 RANDOX LABORATORIES
24.14.1 BUSINESS OVERVIEW
24.14.2 PRODUCT OFFERINGS
24.15 RESPONSE BIOMEDICAL
24.15.1 BUSINESS OVERVIEW
24.15.2 PRODUCT OFFERINGS
24.16 TOSOH
24.16.1 BUSINESS OVERVIEW
24.16.2 PRODUCT OFFERINGS
25 REPORT SUMMARY
25.1 KEY TAKEAWAYS
25.2 STRATEGIC RECOMMENDATIONS
26 QUANTITATIVE SUMMARY
26.1 MARKET BY BIOMARKER TYPE
26.1.1 NORTH AMERICA MARKET BY BIOMARKER TYPE
26.1.2 EUROPE MARKET BY BIOMARKER TYPE
26.1.3 APAC MARKET BY BIOMARKER TYPE
26.1.4 LATIN AMERICA MARKET BY BIOMARKER TYPE
26.1.5 MIDDLE EAST & AFRICA MARKET BY BIOMARKER TYPE
26.2 MARKET BY APPLICATION
26.2.1 NORTH AMERICA MARKET BY APPLICATION
26.2.2 EUROPE MARKET BY APPLICATION
26.2.3 APAC MARKET BY APPLICATION
26.2.4 LATIN AMERICA MARKET BY APPLICATION
26.2.5 MIDDLE EAST & AFRICA MARKET BY APPLICATION
26.3 MARKET BY END-USER
26.3.1 NORTH AMERICA MARKET BY END-USER
26.3.2 EUROPE MARKET BY END-USER
26.3.3 APAC MARKET BY END-USER
26.3.4 LATIN AMERICA MARKET BY END-USER
26.3.5 MIDDLE EAST & AFRICA MARKET BY END-USER
26.4 MARKET BY GEOGRAPHY
26.4.1 TROPONIN MARKET BY GEOGRAPHY
26.4.2 CREATINE KINASE (CK-MB) MARKET BY GEOGRAPHY
26.4.3 MYOGLOBIN MARKET BY GEOGRAPHY
26.4.4 OTHER MARKET BY GEOGRAPHY
26.4.5 ACUTE CORONARY SYNDROME MARKET BY GEOGRAPHY
26.4.6 MYOCARDIAL INFRACTION MARKET BY GEOGRAPHY
26.4.7 CONGESTIVE HEART FAILURE MARKET BY GEOGRAPHY
26.4.8 OTHERS MARKET BY GEOGRAPHY
26.4.9 HOSPITALS MARKET BY GEOGRAPHY
26.4.10 DIAGNOSTIC LABORATORIES MARKET BY GEOGRAPHY
26.4.11 OTHER MARKET BY GEOGRAPHY
27 APPENDIX
27.1 ABBREVIATIONS
EXHIBIT 1 SEGMENTATION OF GLOBAL CARDIAC BIOMARKERS MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH (2022)
EXHIBIT 3 GLOBAL CARDIAC BIOMARKERS MARKET BY GEOGRAPHY: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 4 GLOBAL CARDIAC BIOMARKERS MARKET BY BIOMARKERS TYPE: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 5 GLOBAL CARDIAC BIOMARKERS MARKET BY APPLICATION: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 6 GLOBAL CARDIAC BIOMARKERS MARKET BY END-USER: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 7 IMPACT OF DEVELOPMENT OF HIGHLY SENSITIVE BIOMARKERS FOR RISK STRATIFICATION
EXHIBIT 8 IMPACT OF INTEGRATION OF MULTIPLE CARDIAC BIOMARKERS
EXHIBIT 9 IMPACT OF INCREASING R&D ACTIVITIES OF NOVEL CARDIAC BIOMARKERS
EXHIBIT 10 IMPACT OF GROWING PREVALENCE OF CARDIOVASCULAR DISEASES
EXHIBIT 11 IMPACT OF INCREASING DEMAND FOR POINT-OF-CARE CARDIAC DIAGNOSTICS
EXHIBIT 12 IMPACT OF ADVANCES IN CARDIAC BIOMARKERS
EXHIBIT 13 IMPACT OF LACK OF SPECIFICITY OF CARDIAC BIOMARKERS
EXHIBIT 14 IMPACT OF AVAILABILITY OF NON-LABORATORY TESTS & GENERAL TESTS
EXHIBIT 15 IMPACT OF FALSE DISCOVERIES IN CARDIAC BIOMARKERS RESEARCH
EXHIBIT 16 GLOBAL CARDIAC BIOMARKERS MARKET 2022–2028 ($ BILLION)
EXHIBIT 17 GLOBAL CARDIAC BIOMARKERS MARKET BY GEOGRAPHY: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 18 GLOBAL CARDIAC BIOMARKERS MARKET BY BIOMARKERS TYPE: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 19 GLOBAL CARDIAC BIOMARKERS MARKET BY APPLICATION: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 20 GLOBAL CARDIAC BIOMARKERS MARKET BY END-USER: MARKET OPPORTUNITY OVERVIEW ($ BILLION)
EXHIBIT 21 FIVE FORCES ANALYSIS (2022)
EXHIBIT 22 INCREMENTAL GROWTH BY BIOMARKERS TYPE (2022 & 2028)
EXHIBIT 23 GLOBAL CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022–2028: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 24 GLOBAL CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022–2028: ABSOLUTE GROWTH (%)
EXHIBIT 25 GLOBAL TROPONIN CARDIAC BIOMARKERS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 26 GLOBAL TROPONIN CARDIAC BIOMARKERS MARKET 2022–2028 ($ BILLION)
EXHIBIT 27 GLOBAL CREATINE KINASE (CK-MB) CARDIAC BIOMARKERS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 28 GLOBAL CREATINE KINASE (CK-MB) CARDIAC BIOMARKERS MARKET 2022–2028 ($ BILLION)
EXHIBIT 29 GLOBAL MYOGLOBIN CARDIAC BIOMARKERS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 30 GLOBAL MYOGLOBIN CARDIAC BIOMARKERS MARKET 2022–2028 ($ BILLION)
EXHIBIT 31 GLOBAL OTHER CARDIAC BIOMARKERS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 32 GLOBAL OTHER CARDIAC BIOMARKERS MARKET 2022–2028 ($ BILLION)
EXHIBIT 33 INCREMENTAL GROWTH BY APPLICATION (2022 & 2028)
EXHIBIT 34 GLOBAL CARDIAC BIOMARKERS MARKET BY APPLICATION 2022–2028: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 35 GLOBAL CARDIAC BIOMARKERS MARKET BY APPLICATION 2022–2028: ABSOLUTE GROWTH (%)
EXHIBIT 36 GLOBAL ACUTE CORONARY SYNDROME CARDIAC BIOMARKERS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 37 GLOBAL ACUTE CORONARY SYNDROME CARDIAC BIOMARKERS MARKET 2022–2028 ($ BILLION)
EXHIBIT 38 GLOBAL MYOCARDIAL INFRACTION CARDIAC BIOMARKERS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 39 GLOBAL MYOCARDIAL INFRACTION CARDIAC BIOMARKERS MARKET 2022–2028 ($ BILLION)
EXHIBIT 40 GLOBAL CONGESTIVE HEART FAILURE CARDIAC BIOMARKERS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 41 GLOBAL CONGESTIVE HEART FAILURE CARDIAC BIOMARKERS MARKET 2022–2028 ($ BILLION)
EXHIBIT 42 GLOBAL OTHER CARDIAC BIOMARKERS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 43 GLOBAL OTHER CARDIAC BIOMARKERS MARKET 2022–2028 ($ BILLION)
EXHIBIT 44 INCREMENTAL GROWTH BY END-USER (2022 & 2028)
EXHIBIT 45 GLOBAL CARDIAC BIOMARKERS MARKET BY END-USER 2022–2028: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 46 GLOBAL CARDIAC BIOMARKERS MARKET BY END-USER 2022–2028: ABSOLUTE GROWTH (%)
EXHIBIT 47 GLOBAL HOSPITALS CARDIAC BIOMARKERS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 48 GLOBAL HOSPITALS CARDIAC BIOMARKERS MARKET 2022–2028 ($ BILLION)
EXHIBIT 49 GLOBAL DIAGNOSTIC LABORATORIES CARDIAC BIOMARKERS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 50 GLOBAL DIAGNOSTIC LABORATORIES CARDIAC BIOMARKERS MARKET 2022–2028 ($ BILLION)
EXHIBIT 51 GLOBAL OTHER CARDIAC BIOMARKERS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 52 GLOBAL OTHER CARDIAC BIOMARKERS MARKET 2022–2028 ($ BILLION)
EXHIBIT 53 INCREMENTAL GROWTH BY GEOGRAPHY (2022 & 2028)
EXHIBIT 54 GLOBAL CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022–2028: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 55 GLOBAL CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022–2028: ABSOLUTE GROWTH (%)
EXHIBIT 56 NORTH AMERICA CARDIAC BIOMARKERS MARKET: KEY COUNTRIES BY REVENUE IN 2022 ($ BILLION)
EXHIBIT 57 NORTH AMERICA CARDIAC BIOMARKERS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 58 CARDIAC BIOMARKERS MARKET IN NORTH AMERICA 2022–2028 ($ BILLION)
EXHIBIT 59 INCREMENTAL GROWTH IN NORTH AMERICA (2022 & 2028)
EXHIBIT 60 US CARDIAC BIOMARKERS MARKET 2022–2028 ($ BILLION)
EXHIBIT 61 CARDIAC BIOMARKERS MARKET IN CANADA 2022–2028 ($ BILLION)
EXHIBIT 62 EUROPE CARDIAC BIOMARKERS MARKET: KEY COUNTRIES BY REVENUE IN 2022 ($ BILLION)
EXHIBIT 63 EUROPE CARDIAC BIOMARKERS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 64 CARDIAC BIOMARKERS MARKET IN EUROPE 2022–2028 ($ BILLION)
EXHIBIT 65 INCREMENTAL GROWTH IN EUROPE (2022 & 2028)
EXHIBIT 66 CARDIAC BIOMARKERS MARKET IN GERMANY 2022–2028 ($ BILLION)
EXHIBIT 67 CARDIAC BIOMARKERS MARKET IN FRANCE 2022–2028 ($ BILLION)
EXHIBIT 68 UK CARDIAC BIOMARKERS MARKET 2022–2028 ($ BILLION)
EXHIBIT 69 CARDIAC BIOMARKERS MARKET IN ITALY 2022–2028 ($ BILLION)
EXHIBIT 70 CARDIAC BIOMARKERS MARKET IN SPAIN 2022–2028 ($ BILLION)
EXHIBIT 71 APAC CARDIAC BIOMARKERS MARKET: KEY COUNTRIES BY REVENUE IN 2022 ($ BILLION)
EXHIBIT 72 APAC CARDIAC BIOMARKERS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 73 APAC CARDIAC BIOMARKERS MARKET 2022–2028 ($ BILLION)
EXHIBIT 74 INCREMENTAL GROWTH IN APAC (2022 & 2028)
EXHIBIT 75 CARDIAC BIOMARKERS MARKET IN JAPAN 2022–2028 ($ BILLION)
EXHIBIT 76 CARDIAC BIOMARKERS MARKET IN CHINA 2022–2028 ($ BILLION)
EXHIBIT 77 CARDIAC BIOMARKERS MARKET IN INDIA 2022–2028 ($ BILLION)
EXHIBIT 78 CARDIAC BIOMARKERS MARKET IN SOUTH KOREA 2022–2028 ($ BILLION)
EXHIBIT 79 CARDIAC BIOMARKERS MARKET IN AUSTRALIA 2022–2028 ($ BILLION)
EXHIBIT 80 LATIN AMERICA CARDIAC BIOMARKERS MARKET: KEY COUNTRIES BY REVENUE IN 2022 ($ BILLION)
EXHIBIT 81 LATIN AMERICA CARDIAC BIOMARKERS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 82 CARDIAC BIOMARKERS MARKET IN LATIN AMERICA 2022–2028 ($ BILLION)
EXHIBIT 83 INCREMENTAL GROWTH IN LATIN AMERICA (2022 & 2028)
EXHIBIT 84 CARDIAC BIOMARKERS MARKET IN BRAZIL 2022–2028 ($ BILLION)
EXHIBIT 85 CARDIAC BIOMARKERS MARKET IN MEXICO 2022–2028 ($ BILLION)
EXHIBIT 86 CARDIAC BIOMARKERS MARKET IN ARGENTINA 2022–2028 ($ BILLION)
EXHIBIT 87 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET: KEY COUNTRIES BY REVENUE IN 2022 ($ BILLION)
EXHIBIT 88 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 89 CARDIAC BIOMARKERS MARKET IN MIDDLE EAST & AFRICA 2022–2028 ($ BILLION)
EXHIBIT 90 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA (2022 & 2028)
EXHIBIT 91 CARDIAC BIOMARKERS MARKET IN TURKEY 2022–2028 ($ BILLION)
EXHIBIT 92 CARDIAC BIOMARKERS MARKET IN SOUTH AFRICA 2022–2028 ($ BILLION)
EXHIBIT 93 CARDIAC BIOMARKERS MARKET IN SAUDI ARABIA 2022–2028 ($ BILLION)
EXHIBIT 94 KEY VENDORS OFFERING CARDIAC BIOMARKERS: MARKET DOMINANCE ANALYSIS
EXHIBIT 95 KEY VENDORS OFFERING COMMERCIAL CARDIAC BIOMARKERS: CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 96 ABBOTT: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 97 ABBOTT: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 98 ABBOTT: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 99 ABBOTT: REVENUE BY GEOGRAPHIC REGION 2022 ($ BILLION)
EXHIBIT 100 BIO-RAD LABORATORIES: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 101 BIO-RAD LABORATORIES: R&D EXPENDITURE 2019–2021 ($ MILLION)
EXHIBIT 102 BIO-RAD LABORATORIES: REVENUE BY BUSINESS SEGMENT 2020–2021 ($ MILLION)
EXHIBIT 103 BIO-RAD LABORATORIES: REVENUE BY GEOGRAPHY 2021 ($ MILLION)
EXHIBIT 104 DANAHER: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 105 DANAHER: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 106 DANAHER: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 107 DANAHER: REVENUE BY GEOGRAPHIC REGION 2022 ($ BILLION)
EXHIBIT 108 F. HOFFMANN-LA ROCHE: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 109 F. HOFFMANN-LA ROCHE : R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 110 F. HOFFMANN-LA ROCHE: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLIONS)
EXHIBIT 111 PERKINELMER: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 112 PERKINELMER: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 113 PERKINELMER: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 114 PERKINELMER: REVENUE BY GEOGRAPHIC REGION 2022 ($ BILLION)
EXHIBIT 115 SIEMENS HEALTHINEERS: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 116 SIEMENS HEALTHINEERS: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 117 SIEMENS HEALTHINEERS: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION (2016−2022)
TABLE 3 GLOBAL CARDIAC BIOMARKERS MARKET BY GEOGRAPHY: MARKET SIZE 2022–2028 ($ BILLION)
TABLE 4 GLOBAL CARDIAC BIOMARKERS MARKET BY BIOMARKERS TYPE: MARKET SIZE 2022–2028 ($ BILLION)
TABLE 5 GLOBAL CARDIAC BIOMARKERS MARKET BY APPLICATION: MARKET SIZE 2022–2028 ($ BILLION)
TABLE 6 GLOBAL CARDIAC BIOMARKERS MARKET BY END-USER: MARKET SIZE 2022–2028 ($ BILLION)
TABLE 7 GLOBAL TROPONIN CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 8 GLOBAL TROPONIN CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 9 GLOBAL CREATINE KINASE (CK-MB) CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 10 GLOBAL CREATINE KINASE (CK-MB) CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 11 GLOBAL MYOGLOBIN CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 12 GLOBAL MYOGLOBIN CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 13 GLOBAL OTHER CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 14 GLOBAL OTHER CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 15 GLOBAL ACUTE CORONARY SYNDROME CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 16 GLOBAL ACUTE CORONARY SYNDROME CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 17 GLOBAL MYOCARDIAL INFRACTION CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 18 GLOBAL MYOCARDIAL INFRACTION CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 19 GLOBAL CONGESTIVE HEART FAILURE CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 20 GLOBAL CONGESTIVE HEART FAILURE CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 21 GLOBAL OTHER CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 22 GLOBAL OTHER CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 23 GLOBAL HOSPITALS CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 24 GLOBAL HOSPITALS CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 25 GLOBAL DIAGNOSTIC LABORATORIES CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 26 GLOBAL DIAGNOSTIC LABORATORIES CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 27 GLOBAL OTHER CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 28 GLOBAL OTHER CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 29 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 ($ BILLION)
TABLE 30 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 (%)
TABLE 31 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 32 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 (%)
TABLE 33 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 ($ BILLION)
TABLE 34 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 (%)
TABLE 35 EUROPE CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 ($ BILLION)
TABLE 36 EUROPE CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 (%)
TABLE 37 EUROPE CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 38 EUROPE CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 (%)
TABLE 39 EUROPE CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 ($ BILLION)
TABLE 40 EUROPE CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 (%)
TABLE 41 APAC CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 ($ BILLION)
TABLE 42 APAC CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 (%)
TABLE 43 APAC CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 44 APAC CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 (%)
TABLE 45 APAC CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 ($ BILLION)
TABLE 46 APAC CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 (%)
TABLE 47 LATIN AMERICA CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 ($ BILLION)
TABLE 48 LATIN AMERICA CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 (%)
TABLE 49 LATIN AMERICA CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 50 LATIN AMERICA CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 (%)
TABLE 51 LATIN AMERICA CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 ($ BILLION)
TABLE 52 LATIN AMERICA CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 (%)
TABLE 53 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 ($ BILLION)
TABLE 54 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 (%)
TABLE 55 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 56 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 (%)
TABLE 57 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 ($ BILLION)
TABLE 58 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 (%)
TABLE 59 ABBOTT: MAJOR PRODUCT OFFERINGS
TABLE 60 BIO-RAD LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 61 DANAHER: MAJOR PRODUCT OFFERINGS
TABLE 62 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS
TABLE 63 PERKINELMER: MAJOR PRODUCT OFFERINGS
TABLE 64 SIEMENS HEALTHINEERS: MAJOR PRODUCT OFFERINGS
TABLE 65 ABCAM: MAJOR PRODUCT OFFERINGS
TABLE 66 BIOMÉRIEUX: MAJOR PRODUCT OFFERINGS
TABLE 67 BIOSUPPLY: MAJOR PRODUCT OFFERINGS
TABLE 68 BTNX: MAJOR PRODUCT OFFERINGS
TABLE 69 CARDIOGENICS: MAJOR PRODUCT OFFERINGS
TABLE 70 CREATIVE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 71 DIASORIN: MAJOR PRODUCT OFFERINGS
TABLE 72 LIFE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 73 LUMIRADX: MAJOR PRODUCT OFFERINGS
TABLE 74 MEDIX BIOCHEMICA: MAJOR PRODUCT OFFERINGS
TABLE 75 MESO SCALE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 76 MP BIOMAEDICALS: MAJOR PRODUCT OFFERINGS
TABLE 77 QUIDEL: MAJOR PRODUCT OFFERINGS
TABLE 78 RANDOX LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 79 RESPONSE BIOMEDICAL: MAJOR PRODUCT OFFERINGS
TABLE 80 TOSOH: MAJOR PRODUCT OFFERINGS
TABLE 81 GLOBAL CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 ($ BILLION)
TABLE 82 GLOBAL CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 (%)
TABLE 83 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 ($ BILLION)
TABLE 84 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 (%)
TABLE 85 EUROPE CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 ($ BILLION)
TABLE 86 EUROPE CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 (%)
TABLE 87 APAC CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 ($ BILLION)
TABLE 88 APAC CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 (%)
TABLE 89 LATIN AMERICA CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 ($ BILLION)
TABLE 90 LATIN AMERICA CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 (%)
TABLE 91 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 ($ BILLION)
TABLE 92 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET BY BIOMARKER TYPE 2022−2028 (%)
TABLE 93 GLOBAL CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 94 GLOBAL CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 (%)
TABLE 95 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 96 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 (%)
TABLE 97 EUROPE CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 98 EUROPE CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 (%)
TABLE 99 APAC CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 100 APAC CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 (%)
TABLE 101 LATIN AMERICA CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 102 LATIN AMERICA CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 (%)
TABLE 103 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 104 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET BY APPLICATION 2022−2028 (%)
TABLE 105 GLOBAL CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 ($ BILLION)
TABLE 106 GLOBAL CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 (%)
TABLE 107 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 ($ BILLION)
TABLE 108 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 (%)
TABLE 109 EUROPE CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 ($ BILLION)
TABLE 110 EUROPE CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 (%)
TABLE 111 APAC CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 ($ BILLION)
TABLE 112 APAC CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 (%)
TABLE 113 LATIN AMERICA CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 ($ BILLION)
TABLE 114 LATIN AMERICA CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 (%)
TABLE 115 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 ($ BILLION)
TABLE 116 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET BY END-USER 2022−2028 (%)
TABLE 117 GLOBAL CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 118 GLOBAL CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 119 GLOBAL TROPONIN CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 120 GLOBAL TROPONIN CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 121 GLOBAL CREATINE KINASE (CK-MB) CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 122 GLOBAL CREATINE KINASE (CK-MB) CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 123 GLOBAL MYOGLOBIN CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 124 GLOBAL MYOGLOBIN CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 125 GLOBAL OTHER CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 126 GLOBAL OTHER CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 127 GLOBAL ACUTE CORONARY SYNDROME CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 128 GLOBAL ACUTE CORONARY SYNDROME CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 129 GLOBAL MYOCARDIAL INFRACTION CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 130 GLOBAL MYOCARDIAL INFRACTION CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 131 GLOBAL CONGESTIVE HEART FAILURE CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 132 GLOBAL CONGESTIVE HEART FAILURE CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 133 GLOBAL OTHER CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 134 GLOBAL OTHER CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 135 GLOBAL HOSPITALS CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 136 GLOBAL HOSPITALS CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 137 GLOBAL DIAGNOSTIC LABORATORIES CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 138 GLOBAL DIAGNOSTIC LABORATORIES CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 139 GLOBAL OTHER CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 140 GLOBAL OTHER CARDIAC BIOMARKERS MARKET BY GEOGRAPHY 2022−2028 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
